Phase4 Partners
Phase4 Partners is a prominent venture capital firm based in London, specializing in the healthcare sector. Established in 1999, the firm has evolved its investment approach to cater to the needs of major pharmaceutical companies and sophisticated investors globally. With over $400 million invested in 24 companies across Europe and the United States, Phase4 has been instrumental in the development of several groundbreaking products, including Kyprolis and Ultibro Breezhaler. The firm has a notable track record with successful investments such as Pharmion and Arakis, and it continues to support innovative advancements in medicine, including products currently in clinical trials. Phase4 Partners is a member of the British Private Equity and Venture Capital Association and the European Private Equity and Venture Capital Association.
4 past transactions
Avocode
Debt Financing in 2020
Avocode, Inc. is a software company that specializes in facilitating collaboration between designers and developers. Founded in 2013 and based in New York, it offers a range of tools aimed at streamlining the design-to-development workflow. Avocode's products include features for auto-generating specifications from various design files, conducting design reviews, and enabling online editing of copy directly within design applications such as Adobe XD, Sketch, and Figma. The software allows users to export and share assets, including colors, images, fonts, and CSS, without the need for extensive layer preparation. By acting as a bridge between design and development teams, Avocode enhances efficiency in web and mobile project workflows.
Avocode
Seed Round in 2016
Avocode, Inc. is a software company that specializes in facilitating collaboration between designers and developers. Founded in 2013 and based in New York, it offers a range of tools aimed at streamlining the design-to-development workflow. Avocode's products include features for auto-generating specifications from various design files, conducting design reviews, and enabling online editing of copy directly within design applications such as Adobe XD, Sketch, and Figma. The software allows users to export and share assets, including colors, images, fonts, and CSS, without the need for extensive layer preparation. By acting as a bridge between design and development teams, Avocode enhances efficiency in web and mobile project workflows.
Nabriva Therapeutics
Series B in 2015
Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.
Nabriva Therapeutics
Venture Round in 2009
Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.